A Study to See if Low Level Laser Light Can Help to Treat Toenail Fungus
Launched by ERCHONIA CORPORATION · Feb 27, 2017
Trial Information
Current as of October 17, 2025
Withdrawn
Keywords
ClinConnect Summary
Nail onychomycosis, or fungus infection, is typically caused by a fungus called dermatophytes, but may also be caused by yeasts and molds. These microscopic organisms invade the skin through tiny invisible cuts or through a small separation between the nail and the nail bed. Under conditions of warmth and moisture, the fungi grow and spread. The infection begins as a white or yellow spot under the tip of the nail, and as it spreads deeper into the nail, causes unsightly and potentially painful nail discoloration, thickening and the development of crumbling edges. Onychomycosis occurs more c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Visual clinical presentation of onychomycosis in the target great toenail is distal subungual onychomycosis (DSO), visualized as a nail with normal surface texture and thickness but variable "bays" of white nail that extend from the distal nail tip proximally into the area of the nail bed
- • Clinical involvement of onychomycosis in the target toenail is up to 60%
- • Confirmation of the presence of fungal infection through a positive KOH stain finding and a positive fungal culture finding
- • Identification through fungal culture of the growth of Trichophyton rubrum (T. rubrum) or other common dermatophyte or C. albicans or mixed dermatophyte/Candida infection. In the event of the KOH stain and the fungal culture provide conflicting results, i.e., one is positive and the other negative, resolution may be obtained by a second negative fungal culture finding from a nail clipping from the same nail
- • Subject is willing and able to refrain from employing other (non-study) treatments (traditional or alternative) for his or her toenail onychomycosis throughout study participation.
- • Subject is willing and able to refrain from the use of nail cosmetics such as clear and/or colored nail lacquers throughout study participation
- Exclusion Criteria:
- • Visual clinical presentations of onychomycosis in the target great toenail that are inconsistent with the clinical presentation of distal subungual onychomycosis (DSO), in whole or in part (i.e. indicative of mixed etiology); specifically proximal subungual onychomycosis (PSO); superficial white onychomycosis (SWO); complete dystrophy; other nail changes.
- • Identification through fungal culture of the growth of a rare fungal species (i.e. not Trichophyton rubrum (T. rubrum) or other common dermatophyte or C. albicans or mixed dermatophyte/Candida infection) or non-fungal organisms such as mold or bacteria
- • Less than 2mm clear (unaffected) nail plate length beyond the proximal fold
- • Presence of dermatophytoma (thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed)
- • Infection involving lunula e.g., genetic nail disorders, primentary disorders
- • Severe plantar (moccasin) tinea pedis
- • Psoriasis of the skin and/or nails, lichen planus, or other medical conditions known to induce nail changes
- • Onychogryphosis
- • Trauma from ill-fitting shoes, running, or overly-aggressive nail care
- • Previous toenail surgery
- • Uncontrolled diabetes mellitus
- • Peripheral vascular disease
- • Recurrent cellulitis
- • Lymphatic insufficiency
- • Immune compromise (whether due to underlying medical disorders or immuno-suppressive treatments)
- • Other compromised states of health
- • Known photosensitivity disorder
- • Use of oral antifungal drugs in the prior 6 months
- • Use of topical treatment of the skin or nails within the prior 2 months
- • Any abnormality of the toenail that could prevent a normal appearing nail from occurring if clearing of infection is achieved.
- • Current trauma, open wound on or about the treatment area
- • Deformity of the target toe/toenail secondary to fungal infection/onychomycosis due to prior injury, surgical procedures or another medical condition
- • Pregnant or planning pregnancy prior to the end of study participation
- • Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years
- • Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements
- • Involvement in litigation and/or receiving disability benefits related in any way to the parameters of the study
- • Participation in a clinical study or other type of research in the past 30 days.
About Erchonia Corporation
Erchonia Corporation is a leading innovator in the field of low-level laser therapy (LLLT), dedicated to advancing non-invasive treatment solutions for various medical conditions. With a focus on research and development, Erchonia is committed to delivering safe and effective therapeutic devices that enhance patient outcomes. The company collaborates with healthcare professionals and clinical researchers to validate the efficacy of its technologies through rigorous clinical trials, ensuring compliance with regulatory standards. By merging cutting-edge science with practical applications, Erchonia aims to redefine pain management and promote overall well-being in diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Patients applied
Trial Officials
Antonella Tosti, MD
Principal Investigator
Ted Rosen, MD
Principal Investigator
unaffilliated
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials